MOYAMOYA DISEASE MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-146538 | Health Care
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Moyamoya disease Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL MOYAMOYA DISEASE MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL MOYAMOYA DISEASE MARKET
7.1 GLOBAL MOYAMOYA DISEASE MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL MOYAMOYA DISEASE MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL MOYAMOYA DISEASE MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA MOYAMOYA DISEASE MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Abbott Laboratories (United States)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Boston Scientific Corporation (United States)
16.3 Cephalon Inc (United States)
16.4 Novartis (Switzerland)
16.5 Cordis Corporation (United States)
16.6 Eisai Co Ltd (Japan)
16.7 GE Healthcare (United States)
16.8 Johnson and Johnson (United States)
16.9 GlaxoSmithKline (United Kingdom)
16.10 Medtronic plc (Ireland)
16.11 Merck & Co Inc (United States)
16.12 Sanofi (France)
16.13 Siemens Healthineers (Germany)
16.14 Sunovion Pharmaceuticals (United States)
16.15 UCB Pharma Ltd (Belgium)
16.16 Bausch Health Companies (Canada)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeIschemic
Hemorrhagic
Epileptic
Other
By Treatment
Non-Surgical {Anti-seizure medications and Calcium channel blockers}
Surgical {Vascular bypass surgery and Cerebral Revascularization }
By Age Group
5 to 10 years in children
30 to 50 years in adults
Other
By Diagnosis
Cerebral angiogram
Magnetic resonance imaging (MRI)
Magnetic resonance angiography (MRA)
Computed tomography (CT)
Positron emission tomography (PET)
Electrocardiography ECG
Transcranial Doppler ultrasound
By Surgical Procedure
Indirect {Encephalomyosynangiosis (EMS) Encephaloduroarteriosynangiosis (EDAS)}
Direct {Suturing of a scalp blood vessel the superficial temporal artery}
By Distribution channel
Hospital
Surgical Centers
Diagnostic clinics
Others
Companies
Abbott Laboratories (United States)
Boston Scientific Corporation (United States)
Cephalon Inc (United States)
Novartis (Switzerland)
Cordis Corporation (United States)
Eisai Co Ltd (Japan)
GE Healthcare (United States)
Johnson and Johnson (United States)
GlaxoSmithKline (United Kingdom)
Medtronic plc (Ireland)
Merck & Co Inc (United States)
Sanofi (France)
Siemens Healthineers (Germany)
Sunovion Pharmaceuticals (United States)
UCB Pharma Ltd (Belgium)
Bausch Health Companies (Canada)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.